A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma
BackgroundTumorigenesis and progression are intimately associated with inflammation. However, the inflammatory landscape in soft tissue sarcoma (STS) and its clinical consequences are yet unknown, and more investigation is needed.MethodsRNA-seq expression data for STS and corresponding normal tissue...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.990670/full |
| _version_ | 1798021597455450112 |
|---|---|
| author | Zhehong Li Zhehong Li Honghong Zheng Lirui Liu Zhen Fen Haiying Cao Jilong Yang Jilong Yang Junqiang Wei Junqiang Wei Junqiang Wei |
| author_facet | Zhehong Li Zhehong Li Honghong Zheng Lirui Liu Zhen Fen Haiying Cao Jilong Yang Jilong Yang Junqiang Wei Junqiang Wei Junqiang Wei |
| author_sort | Zhehong Li |
| collection | DOAJ |
| description | BackgroundTumorigenesis and progression are intimately associated with inflammation. However, the inflammatory landscape in soft tissue sarcoma (STS) and its clinical consequences are yet unknown, and more investigation is needed.MethodsRNA-seq expression data for STS and corresponding normal tissues were downloaded from The Cancer Genome Atlas database and the Genotype-Tissue Expression Portal. Differential and prognostic analyses were performed based on known inflammatory response genes from Gene Set Enrichment Analysis (GSEA). We utilized LASSO-Cox analysis to determine hub genes and built an inflammatory score (INFscore) and risk stratification model. Furthermore, a nomogram, including the risk stratification model, was established to predict the prognosis. We further elucidated the characteristics among different risk STS patients by GSEA, gene set variation analysis, and detailed immune infiltration analysis. Finally, the INFscore and risk stratification model in predicting prognosis and depicting immune microenvironment status were verified by pan-cancer analysis.ResultsFive hub genes (HAS2, IL1R1, NMI, SERPINE1, and TACR1) were identified and were used to develop the INFscore. The risk stratification model distinguished the immune microenvironment status and evaluated the efficacy of immunotherapy and chemotherapy in STS. The novel nomogram had good efficacy in predicting the prognosis of STS patients. Finally, a pan-cancer investigation verified the association of INFscore with prognosis and immunity.ConclusionsAccording to the present study, the risk stratification model can be used to evaluate STS prognosis, tumor microenvironment status, immunotherapy, and chemotherapy efficacy. The novel nomogram has an excellent predictive value. Thus, the INFscore and risk stratification model has potential value in assessing the prognosis and immune status of multiple malignancies. |
| first_indexed | 2024-04-11T17:16:09Z |
| format | Article |
| id | doaj.art-b79c15ba73474f7ea3b661f32d7755c1 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T17:16:09Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b79c15ba73474f7ea3b661f32d7755c12022-12-22T04:12:38ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.990670990670A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcomaZhehong Li0Zhehong Li1Honghong Zheng2Lirui Liu3Zhen Fen4Haiying Cao5Jilong Yang6Jilong Yang7Junqiang Wei8Junqiang Wei9Junqiang Wei10Department of Traumatology and Orthopaedics, Affiliated Hospital of Chengde Medical University, Chengde, ChinaDepartment of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of General Surgery, Affiliated Hospital of Chengde Medical University, Chengde, ChinaDepartment of Neonatal Department, Affiliated Hospital of Chengde Medical University, Chengde, ChinaDepartment of Traumatology and Orthopaedics, Affiliated Hospital of Chengde Medical University, Chengde, ChinaDepartment of Traumatology and Orthopaedics, Affiliated Hospital of Chengde Medical University, Chengde, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Traumatology and Orthopaedics, Affiliated Hospital of Chengde Medical University, Chengde, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaBackgroundTumorigenesis and progression are intimately associated with inflammation. However, the inflammatory landscape in soft tissue sarcoma (STS) and its clinical consequences are yet unknown, and more investigation is needed.MethodsRNA-seq expression data for STS and corresponding normal tissues were downloaded from The Cancer Genome Atlas database and the Genotype-Tissue Expression Portal. Differential and prognostic analyses were performed based on known inflammatory response genes from Gene Set Enrichment Analysis (GSEA). We utilized LASSO-Cox analysis to determine hub genes and built an inflammatory score (INFscore) and risk stratification model. Furthermore, a nomogram, including the risk stratification model, was established to predict the prognosis. We further elucidated the characteristics among different risk STS patients by GSEA, gene set variation analysis, and detailed immune infiltration analysis. Finally, the INFscore and risk stratification model in predicting prognosis and depicting immune microenvironment status were verified by pan-cancer analysis.ResultsFive hub genes (HAS2, IL1R1, NMI, SERPINE1, and TACR1) were identified and were used to develop the INFscore. The risk stratification model distinguished the immune microenvironment status and evaluated the efficacy of immunotherapy and chemotherapy in STS. The novel nomogram had good efficacy in predicting the prognosis of STS patients. Finally, a pan-cancer investigation verified the association of INFscore with prognosis and immunity.ConclusionsAccording to the present study, the risk stratification model can be used to evaluate STS prognosis, tumor microenvironment status, immunotherapy, and chemotherapy efficacy. The novel nomogram has an excellent predictive value. Thus, the INFscore and risk stratification model has potential value in assessing the prognosis and immune status of multiple malignancies.https://www.frontiersin.org/articles/10.3389/fonc.2022.990670/fullsoft tissue sarcomainflammatory landscapetumor microenvironmentimmunecancer |
| spellingShingle | Zhehong Li Zhehong Li Honghong Zheng Lirui Liu Zhen Fen Haiying Cao Jilong Yang Jilong Yang Junqiang Wei Junqiang Wei Junqiang Wei A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma Frontiers in Oncology soft tissue sarcoma inflammatory landscape tumor microenvironment immune cancer |
| title | A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma |
| title_full | A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma |
| title_fullStr | A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma |
| title_full_unstemmed | A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma |
| title_short | A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma |
| title_sort | novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma |
| topic | soft tissue sarcoma inflammatory landscape tumor microenvironment immune cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.990670/full |
| work_keys_str_mv | AT zhehongli anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT zhehongli anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT honghongzheng anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT liruiliu anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT zhenfen anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT haiyingcao anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT jilongyang anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT jilongyang anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT junqiangwei anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT junqiangwei anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT junqiangwei anovelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT zhehongli novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT zhehongli novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT honghongzheng novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT liruiliu novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT zhenfen novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT haiyingcao novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT jilongyang novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT jilongyang novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT junqiangwei novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT junqiangwei novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma AT junqiangwei novelinflammatorysignatureforevaluatingimmunemicroenvironmentstatusinsofttissuesarcoma |